SE
SEER.US Seer Inc
- Market cap
- USD 81.5M
- P/E
- -
- P/B
- 0.39x
- ROE
- -29.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SEER.US undervalued?
Graham numberThe Graham number of Seer Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Seer Inc fundamental analysis
No fundamental analysis for Seer Inc yet.
Seer Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorpo…
Full company profileSeer Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Seer Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 116K | 656K | 6.39M | 14.7M | 15.2M | 13.9M | 16.1M | 13.1M |
| Gross Profit | -100K | -585K | -950K | -374K | 384K | 1.45M | 6.83M | 8.01M | 5.71M |
| Operating Income | -6.76M | -16.9M | -33.6M | -71.7M | -98.0M | -105M | -100M | -78.0M | -65.0M |
| EBITDA | -6.28M | -15.3M | -31.2M | -68.6M | -89.0M | -80.7M | -80.3M | -71.9M | -57.0M |
| Net Income | -6.31M | -16.0M | -32.8M | -71.2M | -93.0M | -86.3M | -86.6M | -73.6M | -63.3M |
| EPS | -0.29 | -0.26 | -0.54 | -1.17 | -1.49 | -1.35 | -1.39 | -1.28 | -1.14 |
| Balance Sheet | |||||||||
| Total Assets | 33.7M | 93.2M | 442M | 539M | 488M | 436M | 367M | 296M | 242M |
| Total Liabilities | 3.72M | 5.56M | 10.7M | 36.2M | 40.9M | 39.4M | 39.0M | 36.8M | 28.9M |
| Shareholders' Equity | 30.0M | 87.7M | 432M | 503M | 447M | 397M | 328M | 259M | 213M |
| Cash & Short-term Investments | 31.0M | 86.0M | 432M | 400M | 421M | 316M | 236M | 186M | 156M |
| Total Debt | - | - | - | 23.3M | 29.9M | 28.3M | 26.0M | 23.7M | 21.7M |
| Cash Flow | |||||||||
| Operating Cash Flow | -4.65M | -13.1M | -20.8M | -46.3M | -60.8M | -59.1M | -46.1M | -44.4M | -46.0M |
| Capital Expenditure | 168K | 4.13M | 4.53M | 6.92M | 10.3M | 7.31M | 3.58M | 1.80M | 953K |
| Free Cash Flow | -4.82M | -17.2M | -25.4M | -53.3M | -71.0M | -66.4M | -49.7M | -46.2M | -47.0M |
| Ratios | |||||||||
| ROE | -21.0% | -18.3% | -7.6% | -14.2% | -20.8% | -21.7% | -26.4% | -28.4% | -29.7% |
| ROA | -18.7% | -17.2% | -7.4% | -13.2% | -19.1% | -19.8% | -23.6% | -24.9% | -26.2% |
| Net Profit Margin | - | -13,825.9% | -4,996.2% | -1,113.1% | -633.1% | -568.3% | -620.9% | -456.6% | -485.0% |
| Debt to Equity | - | - | - | 0.05x | 0.07x | 0.07x | 0.08x | 0.09x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Seer Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 72.3M | 1.19 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Seer Inc
- Insiders 15.54%
- Institutions 50.83%
- Public & others 33.63%
- Shares outstanding 55.8M
- Free float 40.4M
Top funds holding SEER.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.22M | 2.19% | 0.00% | Sep 2026 |
| Bridgeway Ultra-Small Company | 380K | 0.68% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 204K | 0.37% | -27.68% | Sep 2026 |
| iShares Micro-Cap ETF | 127K | 0.23% | 0.00% | Oct 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 122K | 0.22% | +63.31% | Jun 2026 |
| Fidelity Total Market Index | 81.3K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 66.0K | 0.12% | 0.00% | Aug 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 64.9K | 0.12% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 61.5K | 0.11% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 55.4K | 0.10% | 0.00% | Sep 2026 |
| GS Absolute Ret Trkr I Acc EUR Hdg | 39.4K | 0.07% | 0.00% | Aug 2026 |
| DFA US Micro Cap I | 37.8K | 0.07% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 34.8K | 0.06% | 0.00% | Sep 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 29.1K | 0.05% | 0.00% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 23.2K | 0.04% | 0.00% | Oct 2026 |
| Dimensional Global Core Equity USD Acc | 14.4K | 0.03% | -0.30% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 12.9K | 0.02% | 0.00% | Sep 2026 |
| Dimensional US Sustainability Core 1 ETF | 11.4K | 0.02% | 0.00% | Oct 2026 |
Top institutions holding SEER.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| SoftBank Group Corp | 5.14M | 9.20% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 2.46M | 4.41% | 0.00% | Jun 2026 |
| BML Capital Management LLC | 2.19M | 3.92% | 0.00% | Sep 2026 |
| Acadian Asset Management LLC | 1.95M | 3.50% | 0.00% | Sep 2026 |
| Vanguard Capital Management, LLC | 1.83M | 3.28% | -6.53% | Jun 2026 |
| BlackRock Inc | 1.43M | 2.56% | -21.59% | Jun 2026 |
| Renaissance Technologies Corp | 988K | 1.77% | +0.21% | Sep 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 825K | 1.48% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 519K | 0.93% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 492K | 0.88% | -3.77% | Jun 2026 |
| Geode Capital Management, LLC | 460K | 0.83% | +8.85% | Jun 2026 |
| Bridgeway Capital Management, LLC | 459K | 0.82% | 0.00% | Jun 2026 |
| Peapod Lane Capital LLC | 445K | 0.80% | +1.57% | Jun 2026 |
| 1888 Investments, LLC | 359K | 0.64% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 247K | 0.44% | +27.02% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 222K | 0.40% | +55.21% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 217K | 0.39% | +0.66% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 213K | 0.38% | 0.00% | Sep 2026 |
| Edgewood Management LLC | 200K | 0.36% | +100.00% | Jun 2026 |
| GSA Capital Partners LLP | 185K | 0.33% | -5.13% | Jun 2026 |
Seer Inc company profile
- Company name
- Seer Inc
- Ticker
- SEER.US
- Exchange
- USA Stocks
- Listed since
- Dec 4, 2020
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 124
- Fiscal year end
- December
- Address
- 3800 Bridge Parkway, Redwood City, CA, United States, 94065
- Phone
- 650 453 0000
- Website
- seer.bio
About Seer Inc
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Seer Inc management
6- Dr. Omid C. Farokhzad M.D., Ph.D.Founder, President, CEO, & Chair of the Board of Directors · born 1969
- Kenny RossChief Operations & Product Officer
- Ms. Marissa DixonChief People Officer
- Mr. Martin Goldberg Ph.D.Senior Vice President of Product Development
- Dr. Asim Siddiqui Ph.D.Senior Vice President of Research & Tech Development
- Mr. Anthony BazarkoChief Commercial Officer